European Society of Human Genetics Conference (ESHG), 2025

Survival, functional outcomes and safety in patients with thymidine kinase 2 deficiency (TK2d) and an age of TK2d symptom onset ≤12 years who received pyrimidine nucleos(t)ide therapy